<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1-548-15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SURVANTA INTRATRACHEAL SUSP.VIAL 8ML
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BERACTANT
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intratracheal use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Endotracheopulmonary instillation, suspension
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        8
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        18
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1742.4
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Abbott Laboratories" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Abbott Laboratories
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 392]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AL-KAMAL IMPORT OFFICE CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ABBVIE Inc.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Survanta contains the active substance beractant which is a natural surfactant extracted from cow&rsquo;s lungs (see section 6) to help your child breathe.</p><p>Your baby will be/has been given Survanta because he or she is at risk of developing, or is suffering from, a condition called Respiratory Distress Syndrome (hyaline membrane disease) which may cause severe breathing difficulties.</p><p>Survanta is indicated for treatment of Respiratory Distress Syndrome (RDS) in newborn premature infants with a birth weight of 700 g or greater and who have had tube inserted and are on a mechanical ventilator to help them breathe.</p><p>Survanta is also used for the treatment of premature babies, when the pregnancy has lasted for less than 32 weeks, at risk of developing RDS.</p><p>Respiratory Distress Syndrome occurs in some babies, particularly premature babies, who lack a substance usually produced in the lungs known as surfactant. This surfactant lines the inside of the lungs, stopping them from sticking together, so that the baby can breathe normally.</p><p>Survanta as a natural surfactant acts in a similar way to your baby&rsquo;s own surfactant helping your baby to breathe normally.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your baby will only be given Survanta if the equipment for ventilation and monitoring babies with Respiratory Distress Syndrome is available.</p><p>After being given Survanta, your baby will continue to be monitored by the doctor or nurse to ensure that the right amount of oxygen is being given.</p><p>&nbsp;</p><p>During the dosing procedure, occasional episodes of slow heartbeat (bradycardia) and/ or oxygen reduction in the circulation have been reported. If these occur, dosing will be stopped and appropriate measures to relieve the condition will be started. After stabilisation, the dosing procedure will be resumed.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The dosage of Survanta varies for each child depending on their body weight. The usual dose is 100 mg Survanta per kg body weight. The doctor will calculate the right dose. Usually the first dose will be given as soon as possible after birth (usually within 15 minutes) or as soon as possible after Respiratory Distress Syndrome has been diagnosed (usually within 8 hours of birth).</p><p>The dose of Survanta will be administered to your baby via a tube already in place in your baby&rsquo;s windpipe. Do not be concerned if your baby is disconnected from its ventilator while Survanta is being administered. To make sure that Survanta reaches all parts of your baby&rsquo;s lungs, the dose is split into smaller doses and your baby&rsquo;s position altered before each part of the dose is given.</p><p>The dose may be repeated up to three times at six hourly intervals within 48 hours. Survanta will be warmed to room temperature before administration to your baby.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Survanta can be associated with side effects although not everybody gets them.</p><p>The following side effects with Survanta are serious and will be managed by your baby&rsquo;s Doctor as necessary during dosing.</p><p><strong>Very common: </strong>affecting more than 1 in 10:</p><p>&middot;&nbsp;&nbsp;&nbsp; Bleeding in the brain. The occurrence of this side effect is no different to what would be expected in untreated babies of the same age.</p><p><strong>Common: </strong>affecting less than 1 in 10</p><p>&middot;&nbsp; Cases of bleeding in the lungs.</p><p>Other Side effects:</p><p><strong>Uncommon: </strong>affecting less than 1 in 100</p><p>&middot;&nbsp; Blockage of the breathing tube that has been inserted into your baby&rsquo;s windpipe.</p><p><strong>If you have any questions about your baby&rsquo;s treatment which are not answered by this leaflet, ask the doctor.</strong></p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side affects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia:</p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>Toll free phone: 8002490000</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Keep out of the sight and reach of children.</strong></p><p>Survanta should not be used after the expiry date shown on the label.</p><p>Survanta should have been stored in a refrigerator (2 to 8&deg;C) and protected from light; however before it is given to your baby it will be warmed to room temperature.</p><p>Survanta must not be frozen. Any product that has been frozen by mistake should be thrown away.</p><p>Each vial of Survanta is for single use only. Used vials with medicine left in them should be thrown away.</p><p>If any vial is not used within 8 hours of re-warming to room temperature it should be thrown away.</p><p>Vials should not be returned to the refrigerator once warmed.</p><p>Medicines should not be disposed of via wastewater or household waste.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-The active substance is beractant which is a mixture containing phospholipids (25 mg/ml), free fatty acids (1.4 -3.5 mg/ml), triglycerides (0.5 -1.75 mg/ml) and protein (0.1 -1.0 mg/ml).</p><p>-The other excipients are sodium chloride, sodium hydroxide, hydrochloric acid, palmitic acid, dipalmitoyl phosphatidylcholine, tripalmitin and water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                -It is a sterile off-white to light brown suspension and is supplied in a single use glass vial containing 8 ml (200 mg phospholipids). Packs of 1, 3, and 10 vials are available.*
*Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>AbbVie Inc.,</p><p>North Chicago, IL 60064. USA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in July 2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي سورفانتا على المادة الفعالة بيراكتنت وهي مادة طبيعية فاعلة بالسطح تستخرج من رئة البقر (انظر القسم ٦) لتساعد طفلك على التنفس</p><p>سيُعطى طفلك سورفانتا لأنه معرض لخطر الإصابة ، أو يعاني من حالة تعرف باسم متلازمة الضائقة التنفسية (مرض غشاء هيليني) والتي قد تسبب صعوبات شديدة في التنفس&nbsp; &nbsp;</p><p>&nbsp; &nbsp;RDS ستعمل سورفانتا لعلاج متلازمة الضائقة التنفسية</p><p>عند المواليد الخدج الذين يكون وزن الولادة لديهم 700 غرام أو للأطفال الذين خضعوا لإدخال انبوباً تنفسياً أو من&nbsp;هم على جهاز&nbsp;&nbsp;التنفس&nbsp;الصناعي&nbsp;وذلك لمساعدتهم على التنفس</p><p>&nbsp;RDS يستخدم سورفانتا &nbsp;أيضاً لعلاج الأطفال الخدج ، عندما يستمر الحمل لمدة أقل من 32 أسبوعا ، في خطر تطوير متلازمة الضائقة التنفسية&nbsp;</p><p>تحدث متلازمة الضائقة التنفسية عند بعض الأطفال، ولا سيما الأطفال الخدج، الذين تفتقر أجسامهم إلى مادة تنتج عادة في الرئتين تعرف باسم المادة الفاعلة على السطح. هذه المادة السطحية تتكون داخل الرئتين، وتمنعها من الالتصاق مع بعضها البعض، بحيث يمكن للطفل أن يتنفس بشكل طبيعي</p><p>يعمل سورفانتا كعامل طبيعي فاعل على السطح بنفس الطريقة التي يعمل بها الفاعل بالسطح الطبيعي الخاص</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>سيُعطى طفلك سورفانتا فقط &nbsp;في حال توفر المعدات اللازمة وتحت الإشراف الطبي للأطفال الذين يعانون من متلازمة الضائقة التنفسية. بعد تلقّي سورفانتا، ستستمر مراقبة طفلك من قبل الطبيب أو الممرضة للتأكد من إعطاء الكمية الصحيحة من الأكسجين</p><p>خلال إجراء الجرعات، تم الإبلاغ عن حدوث نوبات متقطعة من بطء ضربات القلب (بطء القلب) و / أو إنخفاض الأوكسجين في الدورة الدموية. إذا حدث ذلك ، سيتم إيقاف الجرعات وسيتم البدء في اتخاذ التدابير المناسبة لتخفيف الحالة وبعد الاستقرار ، سيتم استئناف الإجراء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تختلف جرعة سورفانتا لكل طفل اعتماداًعلى وزن الجسم. الجرعة المعتادة هي 100 ملغم لكل كجم من وزن الجسم</p><p>سيقوم الطبيب بحساب الجرعة الصحيحة. عادة ما يتم إعطاء الجرعة الأولى في أقرب وقت ممكن بعد الولادة (عادة في غضون 15 دقيقة) أو في أقرب وقت ممكن بعد تشخيص متلازمة الضائقة التنفسية (عادة في غضون 8 ساعات من الولادة)</p><p>سيتم إعطاء جرعة من سورفانتا لطفلك عبر أنبوب وضع مسبقاً في القصبة الهوائية لطفلك. لا تقلق إذا كان طفلك منفصلاً عن جهاز التنفس الصناعي أثناء أخذ الجرعات. للتأكد من وصول سورفانتا إلى جميع أجزاء رئتي طفلك ، يتم تقسيم الجرعة إلى جرعات أصغر وستُغيّر وضعية طفلك قبل إعطاء كل جزء من الجرعة</p><p>يمكن تكرار الجرعة إلى ثلاث مرات على فترات كل ساعة على مدار 48 ساعة. سوف يتم خفض درجة حرارة سورفانتا إلى درجة حرارة الغرفة قبل إعطاءه لطفلك</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هي الحال مع كافة الأدوية، من الممكن أن يسبب <em>سورفانتا</em> تأثيرات جانبية، رغم أنها لا تصيب كافة الأشخاص</p><p>التأثيرات الجانبية التالية الحادثة مع إعطاء <em>سورفانتا</em> خطيرة وسيتم تدبيرها من قبل طبيب الطفل حسب الضرورة في أثناء التجريع</p><p><strong>شائعة جدا:</strong> تصيب أكثر من ١ من ١٠</p><p>&nbsp; &nbsp; &nbsp; &nbsp;نزف في الدماغ. لا يختلف معدّل حدوث هذا التأثير الجانبي عما يمكن توقعه لدى الأطفال غير المعالجين من نفس العمر</p><p><strong>شائعة</strong>: تصيب أقل من ١ من ١٠</p><p>&nbsp; &nbsp; حالات نزف في الرئتين</p><p><strong>التأثيرات الجانبية الأخرى</strong></p><p><strong>غير شائعة:</strong> تصيب أقل من١ من ١٠٠</p><p>&nbsp; &nbsp; &nbsp; انسداد أنبوب التنفس الذي أدخل في القصبة الهوائية لطفلك</p><p>&nbsp;</p><p>إذا كان لديك اي اسئلة أخرى حول علاج طفلك والتي لا تجيب عليها هذه النشرة ، أسال الطبيب</p><p><strong>الإبلاغ عن التأثيرات الجانبية</strong></p><p>إذا أصبت بتأثيرات جانبية، تحدّث إلى طبيبك أو الممرضة. وهذا يشمل أي تأثيرات جانبية غير مدرجة في هذه النشرة. كما يمكنك الإبلاغ عن التأثيرات الجانبية مباشرة (انظر التفاصيل أدناه). بالإبلاغ عن التأثيرات الجانبية يمكنك أيضا المساعدة بتوفير مزيد من المعلومات عن سلامة هذا الدواء.</p><p>للإبلاغ عن أي تأثير(ات) جانبي(ـة):</p><p><strong>&nbsp; &nbsp; &nbsp; &nbsp;</strong><strong>المملكة العربية السعودية</strong></p><p>المركز الوطني للتيقظ والسلامة الدوائية&nbsp;</p><p>فاكس: ٩٦٦١١٢٠٥٧٦٦٢</p><p>اتصل بالمركز الوطني للتيقظ والسلامة الدوائية على هاتف: 2038222-11-966+ تحويلة: 2317-2356-2353-2354-2334-2340</p><p>الهاتف المجاني:&nbsp; 8002490000</p><p>البريد الالكتروني: npc.drug@sfda.gov.sa</p><p>الموقع الالكتروني:&nbsp; www.sfda.gov.sa/npc</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>بلدان مجلس التعاون الخليجي الأخرى</strong></p><p>الرجاء الاتصال بالجهات المختصة المسؤولة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>إحتفظ بهذا الدواء بعيدا عن مرأى الأطفال ومتناول أيديهم</p><p>يجب عدم استخدام الدواء بعد تاريخ انتهاء الصلاحية الموضح علي الملصق</p><p>يُحفظ <em>سورفانتا</em> مبرداً &nbsp;(من ٢ إلى ٨ درجة مئوية) ومحميّا من الضوء ، وقبل إعطائه، يجب تدفئة &nbsp;<em>سورفانتا</em> بوضعه ضمن درجة حرارة الغرفة</p><p>يجب الامتناع عن تجميد <em>سورفانتا</em> كما يجب التخلّص من أي منتج تم تجميده عن طريق الخطأ</p><p>كل قنينة من سورفانتا مخصصة للاستخدام الفردي فقط. يجب التخلص من القارورات المستخدمة مع الأدوية المتبقية</p><p>إذا لم يتم استخدام أي قنينة في غضون 8 ساعات من إعادة التسخين إلى درجة حرارة الغرفة ، فيجب التخلص منها. لا ينبغي أن تعاد القوارير إلى الثلاجة بمجرد تسخينها</p><p>يجب عدم التخلص من الأدوية عن طريق المياه أو النفايات المنزلية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي بيراكتَنت</p><p>&nbsp;phospholipids خليط يحتوي على 25&nbsp;ملغ / مل</p><p>( أحماض دهنية مجانية (1.4 -3.5 ملغم / مل) ، ثلاثي الغليسيريد (0.5 -1.75 ملغم / مل) وبروتين (0.1 - 1 مغ / مل</p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;السواغ الأخرى هي كلوريد الصوديوم ، هيدروكسيد الصوديوم ، حمض الهيدروكلوريك ، حمض البالمتيك ، ثنائي فوسفاتيديل فوسفاتيديل كولين</p><p>والمياه tripalmitin</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>سورفانتا عبارة عن محلول معلق معقم من اللون الأبيض إلى البني الفاتح ويتم تعبئته في قارورة زجاجية تستخدم مرة واحدة تحتوي على 8 مل (200 ملغ من الدهون الفوسفاتية). تتوفر حزم من 1 و 3 و 10 قنينة. ليست جميع أحجام العبوات مسوقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>آبفي إنك&nbsp;</p><p>نورث شيكاغو أي إل ٦٠٠٦٤</p><p>الولايات المتحدة الأمريكية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم آخر تحديث لهذه النشرة في يوليو 2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SURVANTA Intratracheal Suspension 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml contains Beractant equivalent to: 
Phospholipids 	25 mg/ml 
(including disaturated phosphatidylcholines 11.0 - 15.5 mg/ml) 
Triglycerides  0.5 - 1.75 mg/ml 
Free Fatty Acids 1.4 - 3.5 mg/ml
Protein 	0.1 - 1.0 mg/ml 

Excipient with known effect: 3.54mg/ml Sodium 
For the full list of excipients, see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sterile suspension for intratracheal administration
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SURVANTA is indicated for prevention and treatment (&quot;rescue&quot;) of Respiratory Distress Syndrome (RDS) (hyaline membrane disease) in premature infants. SURVANTA significantly reduces the incidence of RDS, mortality due to RDS and air leak complications.</p><p>Prevention:</p><p>In premature infants less than 1250 g birth weight or with evidence of surfactant deficiency, give SURVANTA as soon as possible, preferably within 15 minutes of birth.</p><p>Rescue:</p><p>To treat infants with RDS confirmed by x-ray and requiring mechanical ventilation, give SURVANTA as soon as possible, preferably by eight hours of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For Intratracheal Administration Only.</p><p>SURVANTA should be administered by or under the supervision of clinicians experienced in intubation, ventilator management, and general care of premature infants.</p><p>Marked improvements in oxygenation may occur within minutes of administration of SURVANTA. Therefore, frequent and careful clinical observation and monitoring of systemic oxygenation are essential to avoid hyperoxia.</p><p>Review of audiovisual instructional materials describing dosage and administration procedures is recommended before using SURVANTA. Materials are available upon request.</p><p><strong>Dosage:</strong></p><p>Each dose of SURVANTA is 100 mg of phospholipids/kg birth weight (4 mL/kg). The SURVANTA Dosing Chart shows the total dosage for a range of birth weights.</p><p><strong>SURVANTA DOSING CHART:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td><p>WEIGHT<br />(grams)</p></td><td><p>TOTAL DOSE<br />(mL)</p></td><td><p>WEIGHT<br />(grams)</p></td><td><p>TOTAL DOSE<br />(mL)</p></td></tr></thead><tbody><tr><td><p>600 - 650</p></td><td><p>2.6</p></td><td><p>1301 - 1350</p></td><td><p>5.4</p></td></tr><tr><td><p>651 - 700</p></td><td><p>2.8</p></td><td><p>1351 - 1400</p></td><td><p>5.6</p></td></tr><tr><td><p>701 - 750</p></td><td><p>3.0</p></td><td><p>1401 - 1450</p></td><td><p>5.8</p></td></tr><tr><td><p>751 - 800</p></td><td><p>3.2</p></td><td><p>1451 - 1500</p></td><td><p>6.0</p></td></tr><tr><td><p>801 - 850</p></td><td><p>3.4</p></td><td><p>1501 - 1550</p></td><td><p>6.2</p></td></tr><tr><td><p>851 - 900</p></td><td><p>3.6</p></td><td><p>1551 - 1600</p></td><td><p>6.4</p></td></tr><tr><td><p>901 - 950</p></td><td><p>3.8</p></td><td><p>1601 - 1650</p></td><td><p>6.6</p></td></tr><tr><td><p>951 - 1000</p></td><td><p>4.0</p></td><td><p>1651 - 1700</p></td><td><p>6.8</p></td></tr><tr><td><p>1001 - 1050</p></td><td><p>4.2</p></td><td><p>1701 - 1750</p></td><td><p>7.0</p></td></tr><tr><td><p>1051 - 1100</p></td><td><p>4.4</p></td><td><p>1751 - 1800</p></td><td><p>7.2</p></td></tr><tr><td><p>1101 - 1150</p></td><td><p>4.6</p></td><td><p>1801 - 1850</p></td><td><p>7.4</p></td></tr><tr><td><p>1151 - 1200</p></td><td><p>4.8</p></td><td><p>1851 - 1900</p></td><td><p>7.6</p></td></tr><tr><td><p>1201 - 1250</p></td><td><p>5.0</p></td><td><p>1901 - 1950</p></td><td><p>7.8</p></td></tr><tr><td><p>1251 - 1300</p></td><td><p>5.2</p></td><td><p>1951 - 2000</p></td><td><p>8.0</p></td></tr></tbody></table></td></tr></tbody></table><p>Four doses of SURVANTA can be administered in the first 48 hours of life. Doses should be given no more frequently than every six hours.</p><p>&nbsp;</p><p><strong>Dosing Procedures</strong></p><p>General</p><p>SURVANTA is administered intratracheally by instillation through a 5 French end-hole catheter. The catheter can be inserted into the infant&rsquo;s endotracheal tube without interrupting ventilation by passing the catheter through a neonatal suction valve attached to the endotracheal tube. Alternatively, SURVANTA can be instilled through the catheter by briefly disconnecting the endotracheal tube from the ventilator.</p><p>The neonatal suction valve used for administering SURVANTA should be a type that allows entry of the catheter into the endotracheal tube without interrupting ventilation and also maintains a closed airway circuit system by sealing the valve around the catheter.</p><p>If the neonatal suction valve is used, the catheter should be rigid enough to pass easily into the endotracheal tube. A very soft and pliable catheter may twist or curl within the neonatal suction valve. The length of the catheter should be shortened so that the tip of the catheter protrudes just beyond the end of the endotracheal tube above the infant&rsquo;s carina. SURVANTA should not be instilled into a mainstem bronchus.</p><p>To ensure homogenous distribution of SURVANTA throughout the lungs, each dose is divided into four quarter-doses.</p><p>Each quarter-dose is administered with the infant in a different position. The recommended positions are:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Head and body inclined 5-10&deg; down, head turned to the right</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Head and body inclined 5-10&deg; down, head turned to the left</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Head and body inclined 5-10&deg; up, head turned to the right</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Head and body inclined 5-10&deg; up, head turned to the left</p><p>&nbsp;</p><p>The dosing procedure is facilitated if one person administers the dose while another person positions and monitors the infant.</p><p><strong>First Dose</strong></p><p>Determine the total dose of SURVANTA from the SURVANTA dosing chart based on the infant&#39;s birth weight. Slowly withdraw the entire contents of the vial into a plastic syringe through a large-gauge needle (e.g., at least 20 gauge). Do Not Filter SURVANTA And Avoid Shaking.</p><p>Attach the pre-measured 5 French end-hole catheter to the syringe. Fill the catheter with SURVANTA. Discard excess SURVANTA through the catheter so only the total dose to be given remains in the syringe.</p><p>Before administering SURVANTA, assure proper placement and patency of the endotracheal tube. At the discretion of the clinician, the endotracheal tube may be suctioned before administering SURVANTA. The infant should be allowed to stabilize before proceeding with dosing.</p><p>In the prevention strategy, weigh, intubate and stabilize the infant. Administer the dose as soon as possible after birth, preferably within 15&nbsp;minutes. Position the infant appropriately then gently inject the first fractional dose through the catheter over two to three seconds.</p><p>After administration of the first quarter-dose, remove the catheter from the endotracheal tube. Manually ventilate with a hand-bag with sufficient oxygen to prevent cyanosis, at a rate of 60&nbsp;breaths/minute and sufficient positive pressure to provide adequate air exchange and chest wall excursion.</p><p>In the rescue strategy, the first dose should be given as soon as possible after the infant is placed on a ventilator for management of RDS. In the clinical trials, immediately before instilling the first quarter-dose, the infant&#39;s ventilator settings were changed to rate 60/minute, inspiratory time 0.5&nbsp;second, and FiO<sub>2</sub> 1.0.</p><p>Position the infant appropriately and gently inject the first fractional dose through the catheter over two to three seconds. After administration of the first fractional dose, remove the catheter from the endotracheal tube. Return the infant to the mechanical ventilator.</p><p>In both strategies, ventilate the infant for at least 30 seconds or until stable. Reposition the infant for instillation of the next quarter-dose.</p><p>Instill the remaining quarter-doses using the same procedures. After instillation of each quarter-dose, remove the catheter and ventilate for at least 30 seconds or until the infant is stabilized. After instillation of the final quarter-dose, remove the catheter without flushing it. Do not suction the infant for one hour after dosing unless signs of significant airway obstruction occur.</p><p>After completion of the dosing procedure, resume usual ventilator management and clinical care.</p><p><strong>Repeat Doses:</strong></p><p>The dosage of SURVANTA for repeat doses is also 100 mg phospholipids/kg and is based on the infant&#39;s birth weight. The infant should not be reweighed for determination of the SURVANTA dosage. Use the SURVANTA dosing chart to determine the total dosage.</p><p>The need for additional doses of SURVANTA is determined by evidence of continuing respiratory distress. Using the following criteria for redosing, significant reductions in mortality due to RDS were observed in the multiple-dose clinical trials with SURVANTA.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dose no sooner than six hours after the preceding dose if the infant remains intubated and requires at least 30% inspired oxygen to maintain a PaO2 less than or equal to 80 torr.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Radiographic confirmation of RDS should be obtained before administering additional doses to those who received a prevention dose.</p><p>Prepare SURVANTA and position the infant for administration of each quarter-dose as previously described. After instillation of each quarter-dose, remove the dosing catheter from the endotracheal tube and ventilate the infant for at least 30 seconds or until stable.</p><p>In the clinical studies, ventilator settings used to administer repeat doses were different than those used for the first dose. For repeat doses, the FiO<sub>2</sub> was increased by 0.20 or an amount sufficient to prevent cyanosis. The ventilator delivered a rate of 30/minute with an inspiratory time less than 1.0&nbsp;second. If the infant&#39;s pre-treatment rate was 30 or greater, it was left unchanged during SURVANTA instillation.</p><p>Manual hand-bag ventilation should not be used to administer repeat doses. During the dosing procedure, ventilator settings may be adjusted at the discretion of the clinician to maintain appropriate oxygenation and ventilation.</p><p>After completion of the dosing procedure, resume usual ventilator management and clinical care.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                None known.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SURVANTA is intended for intratracheal use only.</p><p>SURVANTA Can Rapidly Affect Oxygenation And Lung Compliance. Therefore, its use should be restricted to a highly supervised clinical setting with immediate availability of clinicians experienced with intubation, ventilator management, and general care of premature infants. Infants receiving SURVANTA should be frequently monitored with arterial or transcutaneous measurement of systemic oxygen and carbon dioxide.</p><p>During The Dosing Procedure, Transient Episodes Of Bradycardia And Decreased Oxygen Saturation Have Been Reported. If these occur, stop the dosing procedure and initiate appropriate measures to alleviate the condition. After stabilization, resume the dosing procedure.</p><p><strong>General</strong></p><p><strong>Carcinogenesis, Mutagenesis, Impairment of Fertility</strong></p><p>Carcinogenicity studies have not been performed with SURVANTA. SURVANTA was negative when tested in the Ames test for mutagenicity. Using the maximum feasible dose volume, SURVANTA up to 500 mg phospholipids/kg/day (approximately one-third the premature infant dose based on mg/m2/day) was administered subcutaneously to newborn rats for 5 days. The rats reproduced normally and there were no observable adverse effects in their offspring.</p><p>Rales and moist breath sounds can occur transiently after administration. Endotracheal suctioning or other remedial action is not necessary unless clear-cut signs of airway obstruction are present.</p><p>Increased probability of post-treatment nosocomial sepsis in SURVANTA -treated infants was observed in the controlled clinical trials (Table 3). The increased risk for sepsis among SURVANTA -treated infants was not associated with increased mortality among these infants. The causative organisms were similar in treated and control infants. There was no significant difference between groups in the rate of post-treatment infections other than sepsis.</p><p>Use of SURVANTA in infants less than 600 g birth weight or greater than 1750 g birth weights has not been evaluated in controlled trials. There is no controlled experience with use of SURVANTA in conjunction with experimental therapies for RDS (e.g., high-frequency ventilation or extracorporeal membrane oxygenation).</p><p>No information is available on the effects of doses other than 100 mg phospholipids/kg, more than four&nbsp;doses, dosing more frequently than every six hours, or administration after 48 hours of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><strong>Respiratory</strong></p><p>Lung consolidation, blood from the endotracheal tube, deterioration after weaning, respiratory decompensation, subglottic stenosis, paralyzed diaphragm, respiratory failure.</p><p><strong>&nbsp;</strong></p><p><strong>Cardiovascular</strong></p><p>hypotension, hypertension, tachycardia, ventricular tachycardia, aortic thrombosis, cardiac failure, cardio-respiratory arrest, increased apical pulse, persistent fetal circulation, air embolism, total anomalous pulmonary venous return.</p><p><strong>&nbsp;</strong></p><p><strong>Gastrointestinal</strong></p><p>Abdominal distention, hemorrhage, intestinal perforations, volvulus, bowel infarct, feeding intolerance, hepatic failure, stress ulcer.</p><p><strong>&nbsp;</strong></p><p><strong>Renal</strong></p><p>Renal failure, hematuria.</p><p><strong>&nbsp;</strong></p><p><strong>Hematologic</strong></p><p>Coagulopathy, thrombocytopenia, disseminated intravascular coagulation.</p><p><strong>&nbsp;</strong></p><p><strong>Central Nervous System</strong></p><p>seizures</p><p><strong>&nbsp;</strong></p><p><strong>Endocrine/Metabolic</strong></p><p>Adrenal hemorrhage, inappropriate ADH secretion, hyperphosphatemia.</p><p><strong>&nbsp;</strong></p><p><strong>Musculoskeletal</strong></p><p>Inguinal hernia.</p><p><strong>&nbsp;</strong></p><p><strong>Systemic</strong></p><p>fever, deterioration</p><p>&nbsp;</p><p><strong><u>Pediatric population </u></strong></p><p>Summary of the safety profile:</p><p>Intracranial haemorrhage has been observed in patients who received either Beractant or placebo. The incidence of intracranial haemorrhage in all patients is similar to that reported in the literature in this patient population. Pulmonary haemorrhage has also been reported. Blockage of the endotracheal tube by mucous secretions has been reported. No other serious adverse reactions have been reported.</p><p>These are presented in the following table:</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><table border="1" cellspacing="0" cellpadding="0" style="width:580px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class </strong></p></td><td style="vertical-align:top"><p><strong>Frequency </strong></p></td><td style="vertical-align:top"><p><strong>Adverse Reactions </strong></p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Intracranial haemorrhage</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pulmonary haemorrhage</p></td></tr><tr><td style="vertical-align:top"><p>Surgical and Medical Procedures</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Blockage of endotracheal tube by mucous secretions</p></td></tr></tbody></table></td></tr></tbody></table><p>The following frequency categories are used: Very common (&gt;1/10); common (&gt;1/100, &lt;1/10); uncommon (&gt;1/1,000, &lt;1/100).</p><p>No antibody production to Survanta proteins has been observed.</p><p>The most commonly reported adverse experiences were associated with the dosing procedure.</p><p>In the multiple-dose controlled clinical trials, each dose of SURVANTA was divided into four quarter-doses. Each quarter dose was instilled through a catheter inserted into the endotracheal tube by briefly disconnecting the endotracheal tube from the ventilator. Transient bradycardia occurred with 11.9% of doses. Oxygen desaturation occurred with 9.8% of doses.</p><p>Other reactions during the dosing procedure occurred with less than 1% of doses and included endotracheal tube reflux, pallor, vasoconstriction, hypotension, endotracheal tube blockage, hypertension, hypocarbia, hypercarbia, and apnea. No deaths occurred during the dosing procedure, and all reactions resolved with symptomatic treatment.</p><p>The occurrence of concurrent illnesses common in premature infants was evaluated in the controlled trials. The rates in all controlled studies are in Table 2.</p><p><strong>Table 2</strong>&nbsp;:&nbsp;<strong>All Controlled Studies:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td><p><strong>Concurrent Event</strong></p></td><td><p><strong>SURVANTA (%)</strong></p></td><td><p><strong>Control (%)</strong></p></td><td><p><strong>P-Value*</strong></p></td></tr></thead><tbody><tr><td><p>Patent ductus arteriosus</p></td><td><p>46.9</p></td><td><p>47.1</p></td><td><p>0.814</p></td></tr><tr><td><p>Intracranial hemorrhage</p></td><td><p>48.1</p></td><td><p>45.2</p></td><td><p>0.241</p></td></tr><tr><td><p>Severe intracranial hemorrhage</p></td><td><p>24.1</p></td><td><p>23.3</p></td><td><p>0.693</p></td></tr><tr><td><p>Pulmonary air leaks</p></td><td><p>10.9</p></td><td><p>24.7</p></td><td><p>&lt;0.001</p></td></tr><tr><td><p>Pulmonary interstitial emphysema</p></td><td><p>20.2</p></td><td><p>38.4</p></td><td><p>&lt;0.001</p></td></tr><tr><td><p>Necrotizing enterocolitis</p></td><td><p>6.1</p></td><td><p>5.3</p></td><td><p>0.427</p></td></tr><tr><td><p>Apnea</p></td><td><p>65.4</p></td><td><p>59.6</p></td><td><p>0.283</p></td></tr><tr><td><p>Severe apnea</p></td><td><p>46.1</p></td><td><p>42.5</p></td><td><p>0.114</p></td></tr><tr><td><p>Post-treatment sepsis</p></td><td><p>20.7</p></td><td><p>16.1</p></td><td><p>0.019</p></td></tr><tr><td><p>Post-treatment infection</p></td><td><p>10.2</p></td><td><p>9.1</p></td><td><p>0.345</p></td></tr><tr><td><p>Pulmonary hemorrhage</p></td><td><p>7.2</p></td><td><p>5.3</p></td><td><p>0.166</p></td></tr></tbody></table></td></tr></tbody></table><p>&emsp;* P-value comparing groups in controlled studies</p><p>When all controlled studies were pooled, there was no difference in intracranial hemorrhage. However, in one of the single-dose rescue studies and one of the multiple-dose prevention studies, the rate of intracranial hemorrhage was significantly higher in SURVANTA patients than control patients (63.3% versus 30.8%, P=0.001; and 48.8% versus 34.2%, P=0.047, respectively). The rate in a Treatment IND involving approximately 8100 infants was lower than in the controlled trials.</p><p>In the controlled clinical trials, there was no effect of SURVANTA on results of common laboratory tests: white blood cell count serum sodium, potassium, bilirubin, and creatinine.</p><p>More than 4300 pre-treatment and post-treatment serum samples from approximately 1500 patients were tested by Western Blot immunoassay for antibodies to surfactant-associated proteins SP-B and SP-C. No IgG or IgM antibodies were detected.</p><p>Several other complications are known to occur in premature infants. The following conditions were reported in the controlled clinical studies. The rates of the complications were not different in treated and control infants, and none of the complications were attributed to SURVANTA.</p><p><strong>Follow-Up Evaluations</strong></p><p>To date, no long-term complications or sequelae of SURVANTA therapy have been found.</p><p><strong>Single-Dose Studies</strong></p><p>Six-month adjusted-age follow-up evaluations of 232 infants (115 treated) demonstrated no clinically important differences between treatment groups in pulmonary and neurologic sequelae, incidence or severity of retinopathy of prematurity, rehospitalizations, growth, or allergic manifestations.</p><p><strong>Multiple-Dose Studies</strong></p><p>Six-month adjusted age follow-up evaluations have been completed in 631 (345 treated) of 916 surviving infants. There were significantly less cerebral palsy and need for supplemental oxygen in SURVANTA infants than controls. Wheezing at the time of examination was significantly more frequent among SURVANTA infants, although there was no difference in bronchodilator therapy.</p><p>Final twelve-month follow-up data from the multiple-dose studies are available from 521 (272 treated) of 909 surviving infants. There was significantly less wheezing in SURVANTA infants than controls, in contrast to the six-month results. There was no difference in the incidence of cerebral palsy at twelve months.</p><p>Twenty-four month adjusted age evaluations were completed in 429 (226 treated) of 906 surviving infants. There were significantly fewer SURVANTA infants with rhonchi, wheezing, and tachypnea at the time of examination. No other differences were found.</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&minus; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone: 8002490000</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose with SURVANTA has not been reported. Based on animal data, overdose might result in acute airway obstruction. Treatment should be symptomatic and supportive.</p><p>Rales and moist breath sounds can transiently occur after SURVANTA is given, and do not indicate overdose. Endotracheal suctioning or other remedial action is not required unless clear-cut signs of airway obstruction are present.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SURVANTA<sup>&reg;</sup> &nbsp;(beractant) Intratracheal Suspension is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal use only. It is a natural bovine lung extract containing phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins to which colfosceril palmitate (dipalmitoylphosphatidylcholine), palmitic acid, and tripalmitin are added to standardize the composition and to mimic surface-tension lowering properties of natural lung surfactant. The resulting composition provides 25 mg/mL phospholipids (including 11.0-15.5 mg/mL disaturated phosphatidylcholine), 0.5-1.75 mg/mL triglycerides, 1.4-3.5 mg/mL free fatty acids, and less than 1.0 mg/mL protein. It is suspended in 0.9% sodium chloride solution, and heat-sterilized. SURVANTA contains no preservatives. Its protein content consists of two hydrophobic, low molecular weight, surfactant-associated proteins commonly known as SP-B and SP-C. It does not contain the hydrophilic, large molecular weight surfactant-associated protein known as SP-A. Each mL of SURVANTA contains 25 mg of phospholipids. It is an off-white to light brown liquid supplied in single-use glass vials containing 4 mL (100 mg phospholipids) or 8 mL (200 mg phospholipids).</p><table border="1" cellspacing="1" cellpadding="1" style="width:381px"><tbody><tr><td style="width:378px"><table border="1" cellspacing="0" cellpadding="0" style="width:385px"><tbody><tr><td style="vertical-align:top; width:148px"><p>Total Phospholipids</p></td><td style="vertical-align:top; width:236px"><p>approximately 25&nbsp;mg/mL</p></td></tr><tr><td style="vertical-align:top; width:148px"><p>Free Fatty Acids</p></td><td style="vertical-align:top; width:236px"><p>1.4 to 3.5 mg/mL</p></td></tr><tr><td style="vertical-align:top; width:148px"><p>Triglycerides</p></td><td style="vertical-align:top; width:236px"><p>0.5 to 1.75 mg/mL</p></td></tr><tr><td style="vertical-align:top; width:148px"><p>Protein</p></td><td style="vertical-align:top; width:236px"><p>0.1 to 1.0 mg/mL</p></td></tr></tbody></table></td></tr></tbody></table><p>The components are suspended in 0.9% sodium chloride solution and heat-sterilized. SURVANTA<sup>&reg;</sup> contains no preservatives. Its protein content consists of two&nbsp;hydrophobic, low molecular weight, surfactant-associated proteins commonly known as SP-B and SP-C. It does not contain the hydrophilic, large molecular weight surfactant-associated protein known as SP-A.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacologic Properties</u></p><p>Endogenous pulmonary surfactant lowers surface tension of alveolar surfaces during respiration and stabilizes the alveoli against collapse at resting transpulmonary pressures. Deficiency of pulmonary surfactant causes Respiratory Distress Syndrome (RDS) in premature infants. SURVANTA replenishes surfactant and restores surface activity to the lungs of these infants.</p><p><strong>Activity</strong></p><p>In vitro, SURVANTA reproducibly lowers minimum surface tension to less than 8 dynes/cm as measured by the pulsating bubble surfactometer and Wilhelmy Surface Balance. In situ, SURVANTA restores pulmonary compliance to excised rat lungs artificially made surfactant-deficient. In vivo, single SURVANTA<sup>&reg;</sup> doses improve lung pressure-volume measurements, lung compliance, and oxygenation in premature rabbits and sheep.</p><p><strong>Animal Metabolism</strong></p><p>SURVANTA is administered directly to the target organ, the lungs, where biophysical effects occur at the alveolar surface. In surfactant-deficient premature rabbits and lambs, alveolar clearance of radio-labelled lipid components of SURVANTA is rapid. Most of the dose becomes lung-associated within hours of administration, and the lipids enter endogenous surfactant pathways of reutilization and recycling. In surfactant-sufficient adult animals, SURVANTA clearance is more rapid than in premature and young animals. There is less reutilization and recycling of surfactant in adult animals.</p><p>Limited animal experiments have not found effects of SURVANTA on endogenous surfactant metabolism. Precursor incorporation and subsequent secretion of saturated phosphatidylcholine in premature sheep are not changed by SURVANTA treatments.</p><p>No information is available about the metabolic fate of the surfactant-associated proteins in SURVANTA. The metabolic disposition in humans has not been studied.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><u>Description Of Clinical Studies</u></p><p>Clinical effects of SURVANTA were demonstrated in six&nbsp;single-dose and four&nbsp;multiple-dose randomized, multi-center, controlled clinical trials involving approximately 1700 infants. Three open trials, including a Treatment IND, involved more than 8500 infants. Each dose of SURVANTA in all studies was 100&nbsp;mg phospholipids/kg birth weight and was based on published experience with Surfactant TA, a lyophilized powder dosage form of SURVANTA having the same composition.</p><p>Prevention Studies</p><p>Infants of 600 to 1250&nbsp;g birth weight and 23 to 29 weeks estimated gestational age were enrolled in two&nbsp;multiple-dose studies. A dose of SURVANTA was given within 15 minutes of birth to prevent the development of RDS. Up to three&nbsp;additional doses in the first 48 hours, as often as every six hours, were given if RDS subsequently developed and infants required mechanical ventilation with an FiO<sub>2</sub> &ge; 0.30. Results of the studies at 28 days of age are shown in Table 1.</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td>&nbsp; &nbsp; &nbsp;<strong> Study 1&nbsp;</strong></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>&nbsp;</p></td><td><p>SURVANTA</p></td><td><p>Control</p></td><td><p>P-Value</p></td></tr><tr><td><p>Number Infants Studied</p></td><td><p>119</p></td><td><p>124</p></td><td><p>--</p></td></tr><tr><td><p>Incidence of RDS (%)</p></td><td><p>27.6</p></td><td><p>63.5</p></td><td><p>&lt;0.001</p></td></tr><tr><td><p>Death due to RDS (%)</p></td><td><p>2.5</p></td><td><p>19.5</p></td><td><p>&lt;0.001</p></td></tr><tr><td><p>Death or BPD due to RDS (%)</p></td><td><p>48.7</p></td><td><p>52.8</p></td><td><p>0.536</p></td></tr><tr><td><p>Death due to any cause (%)</p></td><td><p>7.6</p></td><td><p>22.8</p></td><td><p>0.001</p></td></tr><tr><td><p>Air Leaks* (%)</p></td><td><p>5.9</p></td><td><p>21.7</p></td><td><p>0.001</p></td></tr><tr><td><p>Pulmonary interstitial emphysema (%)</p></td><td><p>20.8</p></td><td><p>40.0</p></td><td><p>0.001</p></td></tr><tr><td colspan="4"><p>&emsp;* Pneumothorax or pneumopericardium</p></td></tr><tr><td colspan="4"><p><strong>Study 2**</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>SURVANTA</p></td><td><p>Control</p></td><td><p>P-Value</p></td></tr><tr><td><p>Number Infants Studied</p></td><td><p>91</p></td><td><p>96</p></td><td><p>--</p></td></tr><tr><td><p>Incidence of RDS (%)</p></td><td><p>28.6</p></td><td><p>48.3</p></td><td><p>0.007</p></td></tr><tr><td><p>Death due to RDS (%)</p></td><td><p>1.1</p></td><td><p>10.5</p></td><td><p>0.006</p></td></tr><tr><td><p>Death or BPD due to RDS (%)</p></td><td><p>27.5</p></td><td><p>44.2</p></td><td><p>0.018</p></td></tr><tr><td><p>Death due to any cause*** (%)</p></td><td><p>16.5</p></td><td><p>13.7</p></td><td><p>0.633</p></td></tr><tr><td><p>Air Leaks* (%)</p></td><td><p>14.5</p></td><td><p>19.6</p></td><td><p>0.374</p></td></tr><tr><td><p>Pulmonary interstitial emphysema (%)</p></td><td><p>26.5</p></td><td><p>33.2</p></td><td><p>0.298</p></td></tr></tbody></table></td></tr><tr><td>&emsp;* Pneumothorax or pneumopericardium<br />&emsp;** Study discontinued when Treatment IND initiated<br />&emsp;*** No cause of death in the SURVANTA group was significantly increased;<br />&emsp;the higher number of deaths in this group was due to the sum of all causes.</td></tr></tbody></table><p>&nbsp;</p><p>Rescue Studies</p><p>Infants of 600 to 1750 g birth weight with RDS requiring mechanical ventilation and an FiO<sub>2</sub> &ge; 0.40 were enrolled in two&nbsp;multiple-dose rescue studies. The initial dose of SURVANTA was given after RDS developed and before eight hours of age. Infants could receive up to three&nbsp;additional doses in the first 48&nbsp;hours, as often as every six hours, if they required mechanical ventilation and an FiO<sub>2</sub> &ge; 0.30. Results of the studies at 28 days of age are shown in Table 2.</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4"><p>Table 2<br /><strong>Study 3*</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>SURVANTA</p></td><td><p>Control</p></td><td><p>P-Value</p></td></tr><tr><td><p>Number Infants Studied</p></td><td><p>198</p></td><td><p>193</p></td><td><p>--</p></td></tr><tr><td><p>Death due to RDS (%)</p></td><td><p>11.6</p></td><td><p>18.1</p></td><td><p>0.071</p></td></tr><tr><td><p>Death or BPD due to RDS (%)</p></td><td><p>59.1</p></td><td><p>66.8</p></td><td><p>0.102</p></td></tr><tr><td><p>Death due to any cause (%)</p></td><td><p>21.7</p></td><td><p>26.4</p></td><td><p>0.285</p></td></tr><tr><td><p>Air Leaks** (%)</p></td><td><p>11.8</p></td><td><p>29.5</p></td><td><p>&lt;0.001</p></td></tr><tr><td><p>Pulmonary interstitial emphysema (%)</p></td><td><p>16.3</p></td><td><p>34.0</p></td><td><p>&lt;0.001</p></td></tr><tr><td colspan="4"><p><strong>Study 4</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>SURVANTA</p></td><td><p>Control</p></td><td><p>P-Value</p></td></tr><tr><td><p>Number Infants Studied</p></td><td><p>204</p></td><td><p>203</p></td><td><p>--</p></td></tr><tr><td><p>Death due to RDS (%)</p></td><td><p>6.4</p></td><td><p>22.3</p></td><td><p>&lt;0.001</p></td></tr><tr><td><p>Death or BPD due to RDS (%)</p></td><td><p>43.6</p></td><td><p>63.4</p></td><td><p>&lt;0.001</p></td></tr><tr><td><p>Death due to any cause (%)</p></td><td><p>15.2</p></td><td><p>28.2</p></td><td><p>0.001</p></td></tr><tr><td><p>Air Leaks** (%)</p></td><td><p>11.2</p></td><td><p>22.2</p></td><td><p>0.005</p></td></tr><tr><td><p>Pulmonary interstitial emphysema (%)</p></td><td><p>20.8</p></td><td><p>44.4</p></td><td><p>&lt;0.001</p></td></tr><tr><td colspan="4"><p>&emsp;* Study discontinued when Treatment IND Initiated<br />&emsp;** Pneumothorax or pneumopericardium</p></td></tr></tbody></table></td></tr><tr><td>&nbsp;</td></tr></tbody></table><p><strong>Acute Clinical Effects</strong></p><p>Marked improvements in oxygenation may occur within minutes of administration of SURVANTA.</p><p>All controlled clinical studies with SURVANTA provided information regarding the acute effects of SURVANTA on the arterial-alveolar oxygen ratio (a/APO<sub>2</sub>), FiO<sub>2</sub> and mean airway pressure (MAP) during the first 48 to 72 hours of life. Significant improvements in these variables were sustained for 48 to 72 hours in SURVANTA -treated infants in four&nbsp;single-dose and two&nbsp;multiple-dose rescue studies and in two&nbsp;multiple-dose prevention studies. In the single-dose prevention studies, the FiO<sub>2</sub> improved significantly.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Survanta Intratracheal Suspension is supplied in single-use glass vials containing 4 mL or 8&nbsp;mL of Survanta.</p><p>Each milliliter contains 25 mg of phospholipids suspended in 0.9% sodium chloride solution. The color is off-white to light brown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                18 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SURVANTA is stored refrigerated (2 to 8&deg;C). Before administration, SURVANTA should be warmed by standing at room temperature for at least 20 minutes or warmed in the hand for at least eight minutes. Artificial Warming Methods Should Not Be Used. If a prevention dose is to be given, preparation of SURVANTA should begin before the infant&#39;s birth.</p><p>Unopened, unused vials of Survanta that have been warmed to room temperature may be returned to the refrigerator within 24 hours of warming, and stored for future use.</p><p>SURVANTA SHOULD NOT BE WARMED AND RETURNED TO THE REFRIGERATOR MORE THAN ONCE. Each single-use vial of SURVANTA should be entered only once. Used vials with residual drug should be discarded.</p><p>SURVANTA does not require reconstitution or sonication before use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SURVANTA should be inspected visually for discoloration prior to administration. The color of SURVANTA is off-white to light brown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AbbVie Inc., 
North Chicago, 
IL 60064.
USA

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>